$9.64
7.04% yesterday
Nasdaq, Jun 27, 10:14 pm CET
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

EyePoint Pharmaceuticals, Inc. Stock price

$9.64
+3.68 61.75% 1M
+2.44 33.89% 6M
+2.19 29.40% YTD
+0.89 10.17% 1Y
+1.80 22.96% 3Y
+2.04 26.79% 5Y
-27.06 73.73% 10Y
-53.36 84.70% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.73 7.04%
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

Key metrics

Basic
Market capitalization
$663.4m
Enterprise Value
$345.2m
Net debt
$-318.2m
Cash
$318.2m
Shares outstanding
68.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.84 | 15.96
EV/Sales
6.16 | 8.30
EV/FCF
negative
P/B
2.22
Financial Health
Equity Ratio
80.41%
Return on Equity
-38.89%
ROCE
-50.29%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$56.0m | $41.6m
EBITDA
$-159.6m | $272.3m
EBIT
$-161.4m
Net Income
$-146.8m | $-204.9m
Free Cash Flow
$-151.3m
Growth (TTM | estimate)
Revenue
12.04% | -3.94%
EBITDA
-82.38% | 288.72%
EBIT
-82.99%
Net Income
-86.01% | -56.56%
Free Cash Flow
-808.77%
Margin (TTM | estimate)
Gross
93.29%
EBITDA
-284.85% | 655.21%
EBIT
-287.94%
Net
-261.91% | -492.94%
Free Cash Flow
-269.99%
More
EPS
$-2.10
FCF per Share
$-2.20
Short interest
11.74%
Employees
165.00
Rev per Employee
$260.00k
Show more

Is EyePoint Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

EyePoint Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

Buy
95%
Hold
5%

Financial data from EyePoint Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
56 56
12% 12%
100%
- Direct Costs 3.76 3.76
21% 21%
7%
52 52
15% 15%
93%
- Selling and Administrative Expenses 56 56
8% 8%
100%
- Research and Development Expense 158 158
96% 96%
282%
-160 -160
82% 82%
-285%
- Depreciation and Amortization 1.73 1.73
162% 162%
3%
EBIT (Operating Income) EBIT -161 -161
83% 83%
-288%
Net Profit -147 -147
86% 86%
-262%

In millions USD.

Don't miss a Thing! We will send you all news about EyePoint Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EyePoint Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in ...
Neutral
Seeking Alpha
16 days ago
EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent dosing could offer a key advantage over current market leaders Eylea and Vabysmo. Rapid enrollment in Phase 3 trials and robust safety/efficacy data boost confidence, but competition and market fr...
Neutral
MarketBeat
22 days ago
High volatility has plagued markets throughout much of 2025. While many consider this a bad thing, particularly when trends point downward, it can also create opportunities for momentum investors to capture gains when target stocks are up.
More EyePoint Pharmaceuticals, Inc. News

Company Profile

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Duker
Employees 165
Founded 1987
Website eyepointpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today